The aim of the study is to analyse gene typing with the use of the microarray technique (HG-U133A, Affymetrix), differentiating colorectal cancer tissues from tissues assessed histopathologically as healthy ones among a panel of 93 mRNA of gene encoding proteins involved in the activation of cellular signal transduction pathways by insulin-like growth factors. The study was conducted on a group of 8 colorectal cancer patients. Frozen tumor and healthy specimens from the patients were used in molecular tests. Transcript IGF2 differentiated cancer from healthy tissue. Among the genes participating in the cascade of signal transfer in cells activated by IGF, GRB10, PIK3R3, PIK3R1, and IRSI were qualified as differentiating transcripts. IRSI indicated over-expression in tumour. Transcript SMAD2 showed a significant changed in tumour samples (increased expression).
RenehanAGZwahlenMMinderChO'DwyerSTShaletSMEggerM. Insulin-like growth factor, IGF-binding protein-3 and cancer risk: systematic review and meta-regression analysis. Lancet2001; 363: 1346–53.
2.
CohenPClemmonsDRRosenfeldR. Does the GH-IGF axis play a role in cancer pathogenesis?Growth Horm IGF Res2000; 10:297–305.
3.
KaaksRTonioloPAkhmedkhanovALukanovaABiessyCDachaudH. Serum C-Peptide, Insulin-like Growth Factor, IGF-Binding Proteins and Colorectal Cancer Risk in Women. J Natl Cancer Inst2000; 92: 1592–600.
4.
ChanJMStamferMJMaJGannPGazianoJMPollakMGiovannuciE. Insulin-like growth factor-1 and IGF binding protein −3 as a predictor of advanced —stage prostate cancer. Prostate2003; 54: 125–32.
5.
MoschosSJMantzorosCS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology2002; 63:317–32.
6.
O'DellSDDayIN. Molecules in focus: insulin-like growth factor-II. Int J Biochem Cell Biol1998; 30: 767–77.
7.
DupontJPierreAFromentPMoreauC. The insulin-like growth factor axis in cell cycle progression. Horm Metab Res2003; 35:740–50.
8.
HamelersIHVan SchaikRFSipkemaJSussenbachJSSteenberghPH. Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells. J Biol Chem2002; 277: 47645–52.
9.
StrombergTEkmanSGirnitaLDimbergLYLarssonOAxelsonM. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M phase accumulation and apoptosis in multiple myeloma cells. Blood2006; 107:669–78.
10.
StachowiczMMazurekUNowakowska-ZajdelENiedworokEFatygaEMuc-WierzgońM. Leptin and its receptors in obese patients with colorectal cancer. J Biol Regul Homeost Agents2010; 24:287–95.
11.
LeeOHBaeSKMaeMH. Identification of angiogenic properties of insulin—like growth factor II in vitro angiogenesis models. Br J Cancer2000; 82:385–91.
12.
ReinmuthNFanFLiuWParkihAAStoeltzingOJungYDBucanaCDRadinskyRGallicGE. Impact of Insulin—like growth factor receptor-1 function on angiogenesis, growth, metastasis of colon cancer. Lab Invest2002; 82:1377–89.
13.
ZengHDattaKNeidMLiJParangiSMukhopadhyayD. Requirement of different signaling pathways mediated by insulin-like growth factor-1 receptor for proliferation, invasion and VPF/VEGF expression in pancreatic carcinoma cell line. Biochem Biophys Res Commun2003; 302:46–55.
14.
NakamuraMMiyamotoSMaedaH. Matrix metalloproteinase-7 degrades All insulin-like growth factor—binding proteins and facilitates insulin like growth factor bioavailability. Biochem Biophys Res Commun2005; 333:1011–16.
15.
ZhangDSamaniAABrodtP. The role of the IGF-1 receptor In the regulation of matrix metalloproteinases, tumor invasion and metastasis. Horm Metab Res2003; 35:802–808.
16.
LiSRNgCFJBanerjeaAAhmedSHandsRPowarM. Differential expression patterns of insulin-like growth factor 2 gene in human colorectal cancer. Tumor Biol2004; 25:62–68.
17.
ChangQLiYWhiteMFFletcherJAXiaoS. Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: Therapeutic implications. Cancer Res2002; 14:733–40.
18.
GeHWalhoutAJVidalM. Integrating ‘omic’ information: A bridge between genomics and systems biology. Trends Genet2003; 19:551–60.
19.
ChungKYShiaJKemenyNEShahMSchwartzGKTseAHamiltonA. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol2005; 23:1803–10.
20.
BarnesCJOhoshiroKRayalaSKEl-NaggarAKKumarR. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res2007; 13:4291–99.
21.
RyanPDGossPE. The Emerging role of the insulin-like growth factor pathways as a therapeutic target in cancer. Oncologist2008; 13:16–24.
